33 research outputs found
Thermal Insulation System Analysis Tool (TISTool) User's Manual. Version 1.0.0
The Thermal Insulation System Analysis Tool (TISTool) was developed starting in 2004 by Jonathan Demko and James Fesmire. The first edition was written in Excel and Visual BasIc as macros. It included the basic shapes such as a flat plate, cylinder, dished head, and sphere. The data was from several KSC tests that were already in the public literature realm as well as data from NIST and other highly respectable sources. More recently, the tool has been updated with more test data from the Cryogenics Test Laboratory and the tank shape was added. Additionally, the tool was converted to FORTRAN 95 to allow for easier distribution of the material and tool. This document reviews the user instructions for the operation of this system
VALIDATION AND PERFORMANCE OF THE LHC CRYOGENIC SYSTEM THROUGH COMMISSIONING OF THE FIRST SECTOR
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049